AXON Neuroscience (Slovakia)

Institution (Company)

Homepage ROR

Also Known As

AXON Neuroscience (Slovakia)

226

Publications

24.5K

Citations

Authors

161

Concepts

About

AXON Neuroscience (Slovakia) is a company institution in Bratislava, Slovakia known for medicine, neurodegenerative diseases, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	8	13	307
2	Health Sciences	2	17	4.2K
3	Arts	1	1	399
4	Business	1	1	40
5	Language Studies	1	1	20

AXON Neuroscience (Slovakia)

226

Publications

24.5K

Citations

Page 1

	Year	Citations
“Popularity Effect” in User-Generated Content: Evidence from Online Product Reviews Paulo Góes, Mingfeng Lin, Ching‐man Au Yeung Information Systems Research Digital MarketingConsumer ResearchCommunicationOnline Customer BehaviorOnline Product Reviews	2014	399
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial Petr Novák, Reinhold Schmidt, Eva Kontseková, The Lancet Neurology VaccinationAlzheimer's DiseaseVaccine DevelopmentDementiaImmunology	2016	298
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model Eva Kontseková, Norbert Žilka, Branislav Kováčech, Alzheimer s Research & Therapy	2014	243
High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines Yangbing Zhao, Alan Bennett, Zhili Zheng, The Journal of Immunology	2007	213
Human TCR-Binding Affinity is Governed by MHC Class Restriction David K. Cole, Nicholas J. Pumphrey, Jonathan M. Boulter, The Journal of Immunology	2007	206
ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease Petr Novák, Branislav Kováčech, Stanislav Katina, Nature Aging Neurodegenerative DiseasesAlzheimer's DiseaseActive ImmunotherapyMedicinePathological Tau	2021	168
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease Petr Novák, Reinhold Schmidt, Eva Kontseková, Alzheimer s Research & Therapy	2018	140
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease Eva Kontseková, Norbert Žilka, Branislav Kováčech, Alzheimer s Research & Therapy	2014	108
Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors Marco A. Purbhoo, Deborah H. Sutton, Joanna E. Brewer, The Journal of Immunology Cell Surface PresentationSpecific TaasCancer ImmunosurveillanceImmunocytochemical TechniqueT-regulatory Cell	2006	98
Ultrasensitive Detection and Phenotyping of CD4+ T Cells with Optimized HLA Class II Tetramer Staining Thomas J. Scriba, Marco A. Purbhoo, Cheryl L. Day, The Journal of Immunology Cd4+ CellsT-regulatory CellHla ImmunogeneticsImmunologyImmunophenotyping	2005	91

Page 1